Probiotic Lactobacillus Rhamnosus Supplementation Improved Capecitabine Protective Effect Against Gastric Cancer Growth in Male Balb/C Mice Publisher Pubmed



Rahimi AM¹ ; Nabavizadeh F^{1, 2} ; Ashabi G^{1, 2} ; Halimi S³ ; Rahimpour M¹ ; Vahedian J⁴ ; Panahi M⁵ Show Affiliations
Source: Nutrition and Cancer Published:2021

Abstract

The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus) was compared with the capecitabine drug as known used drug against GC. Human GC tissue was obtained from patients with gastric adenocarcinoma and grafted into mice armpit. Probiotic (L. rhamnosus) was given to animals by gavage 2 weeks prior to GC and 4 weeks after GC induction. Also, capecitabine was orally added through feeding tube at the last week of treatment procedure. All grafted animals received cyclosporine a day before the surgery and during the study period to prevent graft rejection. Capecitabine–probiotic complex reduced the size of the axillary implanted GC when compared with control group. Furthermore, combination of capecitabine and probiotic increased apoptotic and necrotic responses in the grafted tumor, blood cells (red blood cells, white blood cells, and platelet counts) in comparison with capecitabine. Probiotic (L. rhamnosus) administration effectively improved the therapeutic index and outcomes, and also, improved the therapeutic effects of the capecitabine. © 2020 Taylor & Francis Group, LLC.